Form D · Biotechnology
Hinge Bio, Inc.
Burlingame, CA · CIK 0001804959
Offering snapshot reported Jan 15, 2025 · SEC filing
- Reported sold
- $30.6M Offering amount: $40.8M
- Investors reported
- 82 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 15, 2025 | Initial | $30,596,388 | No comparison | 82 | SEC filing |
| Feb 1, 2021 | Amendment | $18,000,000 | $5,268,000vs Jan 14, 2021 | 77 | SEC filing |
| Jan 14, 2021 | Amendment | $12,732,000 | $2,445,000vs Jan 7, 2021 | 67 | SEC filing |
| Jan 7, 2021 | Initial | $10,287,000 | No comparison | 47 | SEC filing |
| Apr 28, 2020 | Amendment | $18,191,739 | $0vs Feb 27, 2020 | 100 | SEC filing |
| Feb 27, 2020 | Initial | $18,191,739 | No comparison | 100 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-535383
Portions of the amount under Total Remaining to be Sold is committed to be purchased in a subsequent closing contingent upon milestone achievement.
Source: Form D, filed Jan 15, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Capon | Director, Executive |
| Malcolm Gefter | Director |
| Jeffrey Long Mc Gie | Director |
| John Misha Petkevich | Director |
| J. Misha Petkevich | Director |
| Carin Rollins | Director, Executive |
| Samuel Saks | Director |
| Harold E. Selick, Ph D | Director, Executive |
| Miriam Siekevitz | Executive |
| Alex Silverstein | Director |
| William Unger | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
863 Mitten Road, Suite 100 L
Burlingame, CA, 94010
Burlingame, CA, 94010